BeOne Medicines AG (NASDAQ:ONC) is among the 12 Best Stocks to Buy and Hold for the Next 2 Years.
On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenue of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter and prior-year periods, respectively. Brukinsa, the company’s lymphoma and leukemia treatment, had revenue of $1.1 billion and $3.9 billion for the fourth quarter and full year, respectively, up 38% and 49% from the prior periods.
Following the earnings report, on February 27, Truist Securities raised its price target on BeOne Medicines AG (NASDAQ:ONC) to $412 from $400, while maintaining a Buy rating on the stock. Truist adjusted its price target after incorporating quarterly results, guidance for fiscal 2026, and insights from post-earnings discussions with the company.
Truist Securities noted that BeOne Medicines AG’s (NASDAQ:ONC) fiscal 2026 revenue guidance of $6.2 billion to $6.4 billion roughly exceeds consensus estimates of $6.4 billion and has placed additional pressure on the stock. The analyst said his current outlook for BeOne Medicines AG (NASDAQ:ONC) suggests healthy growth for Brukinsa even without any major expansion of its brands.
Galleri Cancer Screening Kit by Grail Inc. Photo from Grail website
BeOne Medicines AG (NASDAQ:ONC) is a global oncology company that discovers and develops innovative treatments that are more affordable and accessible to cancer patients around the world.
While we recognize ONC’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 13 Hot Stocks to Buy with the Most Upgrade Potential and 10 Materials Stocks with the Most Upgrade Potential to Buy.
Disclosure: None. Follow Insider Monkey on Google News.